BridgeBio to present long-term ATTRibute-CM open-label extension data on acoramidis at ACC 2026

Reuters03-23
BridgeBio to present long-term ATTRibute-CM open-label extension data on acoramidis at ACC 2026
  • BridgeBio reported that long-term efficacy and safety data from the open-label extension (OLE) of its Phase 3 ATTRibute-CM trial of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) will be presented at the ACC Annual Scientific Sessions & Expo on March 30, 2026 by Prem Soman.
  • Additional OLE findings on serum transthyretin concentrations and Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) scores are scheduled for poster presentation on March 28, 2026 by Sarah Cuddy.
  • Another poster will present results on the association between early increases in serum transthyretin with acoramidis and long-term heart failure-related health status in ATTR-CM on March 28, 2026 by Jan Griffin.
  • A separate poster will present results from a US real-world survey on ATTR-CM treatment patterns and preferences on March 30, 2026 by Jill Waldron.
  • BridgeBio said diarrhea occurred in 11.6% of patients receiving Attruby versus 7.6% with placebo, and upper abdominal pain occurred in 5.5% versus 1.4%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676090) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment